Correction to: Communications Biology https://doi.org/10.1038/s42003-021-02866-9; published online 01 December 2021.
In the original version of the Article, the title did not accurate reflect the main findings of the study. In addition, the final sentence of the Abstract and parts of the text referring to references 3–5 were found to be misleading. The following corrections have been made in the PDF and HTML versions of the Article:
Original Title: Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2.
Corrected Title: Amantadine inhibits known and novel ion channels encoded by SARS-CoV-2 in vitro.
Abstract: The final sentence of the abstract was removed (“We therefore propose amantadine as a novel, cheap, readily available and effective way to treat COVID-19”).
Introduction, first paragraph
Original text: A recent retrospective cohort study described an apparent increase in survival in coronavirus disease 2019 (COVID-19) patients treated with amantadine3. Importantly, a study based on self-reported COVID-19 disease among users of amantadine for neurological diseases4 and a small-scale treatment of COVID-19 patients with amantadine5 both supported this observation.
Corrected text: A recent retrospective cohort study evaluating amantadine amongst other antivirals did not find any significant benefit of amantadine in the treatment of coronavirus disease 2019 (COVID-19) patients3. However, a study based on self-reported COVID-19 disease among users of amantadine for neurological diseases4 and a small-scale treatment of COVID-19 patients with amantadine5 suggested a positive impact.
Discussion, second to last paragraph
In the following sentence, the word “use” was incorrect and has been replaced with “further test”:
“We propose to use amantadine as a novel and effective way to treat COVID-19 through its ability to inhibit known (Protein E) and novel (ORF10) ion channels.”
The following sentence has been removed entirely:
Importantly, in the clinic, an apparent protective effect of amantadine in COVID-19 patients has been reported in a retrospective cohort study in Mexico3 and in a small-scale treatment of 15 COVID-19 patients5.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Toft-Bertelsen, T.L., Jeppesen, M.G., Tzortzini, E. et al. Author Correction: Amantadine inhibits known and novel ion channels encoded by SARS-CoV-2 in vitro. Commun Biol 4, 1402 (2021). https://doi.org/10.1038/s42003-021-02940-2
Published:
DOI: https://doi.org/10.1038/s42003-021-02940-2
This article is cited by
-
Ethical challenges of clinical trials with a repurposed drug in outbreaks
Medicine, Health Care and Philosophy (2023)
-
Reply to: How Many SARS-CoV-2 “Viroporins” Are Really Ion Channels?
Communications Biology (2022)
